Balaji Gandhi: Yeah. I mean as you saw in the letter, the way we described MemberConnect and its current iteration is underneath health plan enrollment and patient activation, but — or member activation I’d say. And so Richard, I mean, we’re going to be a little bit close to this in terms of pricing. But I think at a very high level, I think as Randy articulated, very analogous to how our life sciences revenue has been generated and its engagement base. So we essentially get paid by payers, and it’s all types of payers. There’s government payers, right, predominantly in Medicare Advantage. But on some of the activation stuff, it could be a commercial plan. It could be a value-based care plan with a pay buyer. And they’re paying us on a per engagement basis.
There’s a range of expectations there in terms of what we can get. It’s still early days, but there’s two variables in that. It’s the number of people we can engage and how much we get paid for each. So I’m not trying to estimate but…
Richard Close: Can I — yeah. Can I slip there one more in regarding that?
Balaji Gandhi: Sure. Thankfully. Yes.
Richard Close: Yeah. So I mean are you essentially getting paid for lead flow? And if they activate or sign up for the plan, is there any type of residual revenue associated with that or…
Balaji Gandhi: No. And hence, again, the description, we renamed the revenue line with revenue category, and it’s engagement based, non-recurring.
Randy Rasmussen: Yeah. There’s no residual today.
Richard Close: Excellent. Thank you.
Operator: Your next question comes from the line of Jessica Tassan with Piper Sandler. Your line is now open.
Jessica Tassan: Thank you, and congrats on the good quarter. I was just curious to know, so when you sign a new provider client to the network solutions that you’ve contracted more broadly automatically extend to that provider’s patients assuming he’s a network or how does that work?
Randy Rasmussen: Yeah. Assuming so when we set a new provider, if they give us permission, then they would be part of the network and we could deliver digital engagement for either life science or MemberConnect.
Jessica Tassan: Got it. And then just — I’m sorry.
Randy Rasmussen: Go ahead.
Jessica Tassan: Just as you guys diversify the revenue streams, is there any thought to potentially offsetting some of the subscription burden incumbent upon the provider with some of these alternative sources of revenue or should we still expect that the kind of total addressable opportunity per subscriptions on a per provider basis is the same as it always was? And that’s it for me. Thank you.
Randy Rasmussen: No. We expect subscription to stay where it was. We — this isn’t an alternative. This is in lieu of (ph).
Jessica Tassan: Got it. Thank you.
Randy Rasmussen: Thanks, Jess.
Operator: Your next question comes from the line of Stephanie Davis with SVB. Your line is now open.
Stephanie Davis: Hey, guys. Congrats on a great quarter. I
Chaim Indig: Thank you.
Stephanie Davis: I was hoping to prod a little on that transaction you comment because you said that upmarket, you were seeing a lot of price gouging from the other merchant acquirers. At 3%, like you guys are solidly 50 bps above market. Is there anything else in your transaction yield beyond just the route merchant acquiring that we should know about or is pricing really that bad in the market?
Randy Rasmussen: I would say pricing is really that bad, right? Just it is unbelievable. People are taking advantage of our hospitals in America, it is very upsetting, Stephanie.
Stephanie Davis: That’s insane. So with that in mind, would you go to something more in line with a traditional merchant acquiring? And does that mean you’re not bumping into the traditional merchant acquirers like the Bank of America Merchant Services and Chase FinTechs of the world or are they just kind of taking advantage of it? And they’re still doing that with the 3% pricing.
